Details

Upravna overitev : diplomsko delo visokošolskega programa
ID Tončič, Minka (Author), ID Kovač, Polonca (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (510,51 KB)
MD5: 23D3C6E83BCB7F3AAD97B149C6F53AD8
PID: 20.500.12556/rul/0241710f-a534-44a0-8612-7502795d48d3

Language:Slovenian
Keywords:držana uprava, upravni postopek, overitev, diplomske naloge
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[M. Tončič]
Year:2009
Number of pages:V, 52 str.
PID:20.500.12556/RUL-2105 This link opens in a new window
UDC:351(043.2)
COBISS.SI-ID:3130542 This link opens in a new window
Publication date in RUL:11.07.2014
Views:8439
Downloads:457
Metadata:XML DC-XML DC-RDF
:
TONČIČ, Minka, 2009, Upravna overitev : diplomsko delo visokošolskega programa [online]. Bachelor’s thesis. Ljubljana : M. Tončič. [Accessed 19 August 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=2105
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back